Literature DB >> 33234660

Retrospective cohort study of admission timing and mortality following COVID-19 infection in England.

Ahmed Alaa1, Zhaozhi Qian2, Jem Rashbass3, Jonathan Benger4, Mihaela van der Schaar2.   

Abstract

OBJECTIVES: We investigated whether the timing of hospital admission is associated with the risk of mortality for patients with COVID-19 in England, and the factors associated with a longer interval between symptom onset and hospital admission.
DESIGN: Retrospective observational cohort study of data collected by the COVID-19 Hospitalisation in England Surveillance System (CHESS). Data were analysed using multivariate regression analysis.
SETTING: Acute hospital trusts in England that submit data to CHESS routinely. PARTICIPANTS: Of 14 150 patients included in CHESS until 13 May 2020, 401 lacked a confirmed diagnosis of COVID-19 and 7666 lacked a recorded date of symptom onset. This left 6083 individuals, of whom 15 were excluded because the time between symptom onset and hospital admission exceeded 3 months. The study cohort therefore comprised 6068 unique individuals. MAIN OUTCOME MEASURES: All-cause mortality during the study period.
RESULTS: Timing of hospital admission was an independent predictor of mortality following adjustment for age, sex, comorbidities, ethnicity and obesity. Each additional day between symptom onset and hospital admission was associated with a 1% increase in mortality risk (HR 1.01; p<0.005). Healthcare workers were most likely to have an increased interval between symptom onset and hospital admission, as were people from Black, Asian and minority ethnic (BAME) backgrounds, and patients with obesity.
CONCLUSION: The timing of hospital admission is associated with mortality in patients with COVID-19. Healthcare workers and individuals from a BAME background are at greater risk of later admission, which may contribute to reports of poorer outcomes in these groups. Strategies to identify and admit patients with high-risk and those showing signs of deterioration in a timely way may reduce the consequent mortality from COVID-19, and should be explored. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  health policy; infectious diseases; public health

Mesh:

Year:  2020        PMID: 33234660      PMCID: PMC7684820          DOI: 10.1136/bmjopen-2020-042712

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


We used all available data from a large observational data set, and analysed this using two multivariate regression models. Our findings are internally consistent and statistically and clinically significant. This research has several limitations. Of 13 749 patients with a confirmed diagnosis of COVID-19, only 6083 could be included in the study, and the date of symptom onset was self-reported, rather than objectively verified. Our data are observational and should be interpreted with caution; the results may have been influenced by unmeasured confounders.

Background

On 31 December 2019, the WHO China country office was informed of 44 cases of pneumonia of unknown cause in Wuhan city, China.1 By 14 June 2020, more than 7.8 million cases of COVID-19 disease caused by the SARS-CoV-2 had been reported across 188 countries and regions, resulting in 431 000 deaths.2 Throughout the early stages of the pandemic clinicians treating patients with COVID-19 reported that infected individuals were tending to present later than expected to hospital services, with many profoundly hypoxic and requiring respiratory support soon after admission. This has been attributed to the phenomenon of ‘silent hypoxia’; in COVID-19 infection, oxygen levels may fall dangerously low without an individual becoming aware of this.3 Another reason for later presentation in the UK may have been the public’s desire to ‘protect the National Health Service (NHS)’,4 and also a tendency to stay away from hospitals because of concerns that there was a risk of coming into contact with the disease there.5 However, late presentation to hospital services delays the correction of hypoxia and the initiation of potentially life-saving treatments including respiratory support and dexamethasone.6 We hypothesised that later hospital admission may be associated with increased mortality. We also hypothesised that some patient groups may be more prone to later hospital admission, providing an opportunity to deliver interventions to those most at risk. To determine whether the timing of hospital admission is associated with mortality for patients diagnosed with COVID-19 infection. To identify the characteristics of patients with COVID-19 most at risk of later hospital admission.

Methods

Study design

We completed a retrospective observational cohort study using data from the COVID-19 Hospitalisation in England Surveillance System (CHESS), established by Public Health England to collect routine data during the COVID-19 pandemic.

Setting

We included data collected by CHESS between 8 February and 13 April 2020. During this time, data returns were received from 94 of 152 (62%) of all acute hospital trusts in England.

Participants

Participants were individuals included in the CHESS database during the study period. We excluded patients without a confirmed diagnosis of COVID-19, those for whom the date of symptom onset was not recorded and those in whom the recorded date of symptom onset was more than 3 months before or after the date of hospital admission (on the assumption that a data entry error had occurred).

Variables

A set of 23 case-level variables were identified for each patient, as follows.

Demographic

Age; sex; obesity; ethnicity (White, Asian, Black, other) and healthcare worker.

Comorbidities

Respiratory; asthma; diabetes; cardiovascular; hypertension; renal; liver; immunosuppressive disease and immunosuppressive treatment.

Timing of hospitalisation

The timing of hospitalisation was a continuous variable defined as the number of days between symptom onset and admission to hospital. Patients hospitalised before symptom onset were assumed to have been admitted for a reason other than COVID-19: either they were infected but asymptomatic on admission or they became infected while in hospital. The primary outcome was all-cause mortality during the study follow-up period. Patients who remained in hospital at the end of the follow-up period (13 May 2020) were considered to be censored.

Sample size

This was a consecutive sample, using all available data.

Statistical methods

Two multivariate regression models were used to estimate the impact of admission timing on patient mortality risk, and identify the patient characteristics associated with later hospital admission. A Cox proportional hazards regression model using the 22 case-level variables was fit with the patients’ survival and follow-up time as outcomes. In addition, a binary logistic regression model was fit to infer the association between the 21 case-level variables (excluding the timing of hospital admission) with a binary indicator for a ‘delayed’ hospital admission. Here, a delayed hospital admission was defined using a binary indicator to indicate whether each patient’s hospital admission delay was greater than the population median delay.

Results

A total of 14 150 patients with COVID-19 were included in the CHESS database between 8 February and 13 April 2020. After applying the exclusion criteria, 6068 unique individuals were included in the final analysis (figure 1). Of these 6068 patients, 843 patients (14%) developed symptoms of COVID-19 while a hospital inpatient, whereas 5225 patients (86%) were admitted to hospital after exhibiting COVID-19 symptoms, with a mean interval of 4.6 days between symptom onset and hospital admission.
Figure 1

Patients’ flow diagram. CHESS, COVID-19 Hospitalisation in England Surveillance System.

Patients’ flow diagram. CHESS, COVID-19 Hospitalisation in England Surveillance System. A comparison of the patients included in the final analysis and in the whole CHESS population is shown in table 1. In general, the analysis cohort appears representative of all those included in the CHESS database during this time period; however, there are some differences in obesity, White ethnicity and the number of recorded comorbidities.
Table 1

Comparison of the included cohort with all those recorded in the CHESS database

Analysis cohort (n=6068)All CHESS patients (n=14 150)
Median age66 years65 years
Male sex61%60%
Obesity12%7%
White ethnicity58%46%
Asian ethnicity6.6%5.1%
Black ethnicity19%15%
Number of comorbidities1.00.65

CHESS, COVID-19 Hospitalisation in England Surveillance System.

Comparison of the included cohort with all those recorded in the CHESS database CHESS, COVID-19 Hospitalisation in England Surveillance System. The characteristics of the included patients, according to the timing of admission, are shown in table 2. Several differences are apparent. Patients admitted after exhibiting COVID-19 symptoms were younger, more likely to be obese and more likely to be from Black, Asian and minority ethnic (BAME) backgrounds.
Table 2

Characteristics of the included patients, according to the timing of admission

Hospitalised before symptom onsetHospitalised after symptom onsetAll patients
Median age79 years64 years68 years
Male sex52%62%61%
White ethnicity63%57%59%
Asian ethnicity3%7%7%
Black ethnicity1%2%2%
Number of comorbidities1.0/patient1.2/patient1.0/patient
Characteristics of the included patients, according to the timing of admission Kaplan-Meier survival curves for the subcohorts of patients admitted to hospital after more than 1, 2 and 3 weeks of exhibiting COVID-19 symptoms show a higher mortality risk than the overall population (figure 2, panels A-C). After adjusting for all covariates via the multivariate Cox regression model, the fitted coefficients indicate that later hospital admission is an independent and statistically significant predictor of mortality, with a hazard ratio (HR) of 1.01 (ie, a 1% elevation in mortality risk for each additional day between symptom onset and hospital admission, p<0.005; figure 3). Of particular note is the observation that being hospitalised before symptom onset (which implies that the patient developed COVID-19 while a hospital inpatient) is associated with a considerably reduced risk of mortality (HR 0.52; 95% CIs 0.45 to 0.61).
Figure 2

Kaplan-Meier survival curves for the subcohorts of patients admitted to hospital after more than 1 week (A), 2 weeks (B) and 3 weeks (C) of exhibiting COVID-19 symptoms.

Figure 3

Hazard ratios for mortality (based on a Cox proportional hazards regression model).

Kaplan-Meier survival curves for the subcohorts of patients admitted to hospital after more than 1 week (A), 2 weeks (B) and 3 weeks (C) of exhibiting COVID-19 symptoms. Hazard ratios for mortality (based on a Cox proportional hazards regression model). The observed predictors of later hospitalisation were examined using odds ratios (ORs) based on the fitted logistic regression model, and are shown in figure 4. There is a striking association with later presentation among healthcare workers (OR 4.87; 95% CIs 3.31 to 6.53). Obese individuals and those who from a BAME background were also more likely to present later to hospital services.
Figure 4

Predictors of later hospital admission.

Predictors of later hospital admission.

Discussion

We have shown that later hospital admission is associated with an increased risk of mortality following infection with COVID-19. Later admission is a predictor of poor outcome even after adjustment for age, sex, ethnicity, obesity and comorbidities, and suggests that timely hospital admission could reduce mortality in selected individuals who are at high risk of complications or showing signs of deterioration. We have also shown that certain characteristics are associated with later hospital admission, and identified several ‘at-risk’ groups to which specific interventions could be addressed. Our findings support the hypothesis that earlier detection of deterioration and timely admission could reduce mortality, particularly as knowledge of the disease grows, and treatment modalities improve.6 7 It has been observed previously that early and intensive hospital intervention can improve outcomes in patients with COVID-19;8 however, the mechanisms by which this occurs are not yet fully understood. Death in patients with COVID-19 is commonly caused by an unregulated immune response, sometimes described as a ‘cytokine storm’,9 however little is known about the cause and prevention of this phenomenon. Correction of hypoxia and physiological optimisation is likely to play a part, and recent interest has also focused on steroids and anticoagulation to reduce inflammation and the abnormal coagulation that occurs during severe COVID-19 disease.6 10 It is therefore not surprising that hospital admission is an effective treatment for serious COVID-19 infection, and in common with other effective treatments for communicable diseases,11 the earlier it is delivered the more effective it tends to be. The role of timely hospital admission is further supported by our observation that those patients who developed symptoms of COVID-19 while a hospital inpatient had a significantly reduced mortality. This is supported by the findings of other observational research that found patients with nosocomial infection had a lower mortality than patients who acquired COVID-19 in the community.12 We found that healthcare workers are significantly more likely to experience later hospital admission, when compared with other patients with COVID-19. This is, perhaps, intuitive, since healthcare workers may wish to avoid being a ‘burden’ to their colleagues, making them particularly reluctant to use hospital services.13 We also observed a strong association with later admission among individuals from a BAME background, as well as those with obesity. Later presentation by people in these groups could be a factor in the excess mortality that has been reported in previous analyses,14–16 and this is further supported by research from the USA identifying that minority ethnic patients admitted with confirmed COVID-19 infection are more likely to present with increased disease severity on admission chest radiographs.17 Strategies designed to encourage individuals from these groups to seek help at an earlier stage may prove effective in reducing these disparities. This study has several limitations. Of 13 749 patients with a confirmed diagnosis of COVID-19, 7666 (56%) had no recorded date of symptom onset, and the exclusion of a further 15 patients with a date of symptom onset more than 3 months from hospital admission suggests weaknesses in the quality of the data recorded in CHESS. While the date of hospital admission was objectively verifiable, the date of symptom onset was self-reported and may have been subject to recall bias. We believe our findings are generalisable to adults diagnosed with COVID-19 and admitted to hospital; however, there were too few children in the sample to draw conclusions regarding the paediatric population. The most significant weakness is the use of observational data which makes it possible that our findings were influenced by unmeasured confounders. We have demonstrated an association between later hospital admission and subsequent mortality for patients diagnosed with COVID-19. However, for the majority of individuals, COVID-19 is a mild illness,18 and it would not be practical to admit all diagnosed cases. We therefore propose further studies to evaluate the effect of identifying and monitoring high-risk patients in the community following diagnosis. It has been suggested that home measurements of oxygen saturation, using a simple pulse oximeter, could detect ‘silent hypoxia’ at an early stage,7 and early trials of this approach have been encouraging.19 A policy of prompt hospital admission for those showing deterioration has the potential to improve outcomes and save lives. This should be combined with specific education of the public and particularly those groups who may present later to hospital services.

Conclusion

We have demonstrated an independent association between the timing of hospital admission and subsequent mortality in patients diagnosed with COVID-19. Those at greatest risk of later hospital admission are healthcare workers, people with obesity and individuals from a BAME background, and this may be a factor in the poorer outcomes that have been reported in these patient groups. Strategies to identify and admit patients showing signs of deterioration in a timely way may reduce the consequent mortality from COVID-19, and should be explored further.
  15 in total

1.  Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms.

Authors:  Naveed Sattar; Iain B McInnes; John J V McMurray
Journal:  Circulation       Date:  2020-04-22       Impact factor: 29.690

2.  Time to Treatment and Mortality during Mandated Emergency Care for Sepsis.

Authors:  Christopher W Seymour; Foster Gesten; Hallie C Prescott; Marcus E Friedrich; Theodore J Iwashyna; Gary S Phillips; Stanley Lemeshow; Tiffany Osborn; Kathleen M Terry; Mitchell M Levy
Journal:  N Engl J Med       Date:  2017-05-21       Impact factor: 91.245

Review 3.  Preliminary predictive criteria for COVID-19 cytokine storm.

Authors:  Roberto Caricchio; Marcello Gallucci; Chandra Dass; Xinyan Zhang; Stefania Gallucci; David Fleece; Michael Bromberg; Gerard J Criner
Journal:  Ann Rheum Dis       Date:  2020-09-25       Impact factor: 19.103

4.  Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople).

Authors:  B Carter; J T Collins; F Barlow-Pay; F Rickard; E Bruce; A Verduri; T J Quinn; E Mitchell; A Price; A Vilches-Moraga; M J Stechman; R Short; A Einarsson; P Braude; S Moug; P K Myint; J Hewitt; L Pearce; K McCarthy
Journal:  J Hosp Infect       Date:  2020-07-21       Impact factor: 3.926

5.  Delayed access to care and late presentations in children during the COVID-19 pandemic: a snapshot survey of 4075 paediatricians in the UK and Ireland.

Authors:  Richard M Lynn; Jacob L Avis; Simon Lenton; Zahin Amin-Chowdhury; Shamez N Ladhani
Journal:  Arch Dis Child       Date:  2020-06-25       Impact factor: 3.791

6.  COVID-19 patients with respiratory failure: what can we learn from aviation medicine?

Authors:  William Ottestad; Signe Søvik
Journal:  Br J Anaesth       Date:  2020-04-18       Impact factor: 9.166

7.  Racial and Ethnic Disparities in Disease Severity on Admission Chest Radiographs among Patients Admitted with Confirmed Coronavirus Disease 2019: A Retrospective Cohort Study.

Authors:  Nicholos P Joseph; Nicholas J Reid; Avik Som; Matthew D Li; Emily P Hyle; Caitlin M Dugdale; Min Lang; Joseph R Betancourt; Francis Deng; Dexter P Mendoza; Brent P Little; Anand K Narayan; Efrén J Flores
Journal:  Radiology       Date:  2020-07-16       Impact factor: 11.105

8.  Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.

Authors:  Sakiko Tabata; Kazuo Imai; Shuichi Kawano; Mayu Ikeda; Tatsuya Kodama; Kazuyasu Miyoshi; Hirofumi Obinata; Satoshi Mimura; Tsutomu Kodera; Manabu Kitagaki; Michiya Sato; Satoshi Suzuki; Toshimitsu Ito; Yasuhide Uwabe; Kaku Tamura
Journal:  Lancet Infect Dis       Date:  2020-06-12       Impact factor: 25.071

9.  Pulse Oximetry as a Biomarker for Early Identification and Hospitalization of COVID-19 Pneumonia.

Authors:  Richard M Levitan
Journal:  Acad Emerg Med       Date:  2020-08-16       Impact factor: 5.221

10.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

View more
  14 in total

1.  Comparative assessment of methods for short-term forecasts of COVID-19 hospital admissions in England at the local level.

Authors:  Sophie Meakin; Sam Abbott; Nikos Bosse; James Munday; Hugo Gruson; Joel Hellewell; Katharine Sherratt; Sebastian Funk
Journal:  BMC Med       Date:  2022-02-21       Impact factor: 8.775

2.  Ferritin, blood urea nitrogen, and high chest CT score determines ICU admission in COVID-19 positive UAE patients: A single center retrospective study.

Authors:  Riyad Bendardaf; Poorna Manasa Bhamidimarri; Zainab Al-Abadla; Dima Zein; Noura Alkhayal; Ramy Refaat Georgy; Feda Al Ali; Alaa Elkhider; Sadeq Qadri; Rifat Hamoudi; Salah Abusnana
Journal:  PLoS One       Date:  2022-07-19       Impact factor: 3.752

3.  Changes in COVID-19 in-hospital mortality in hospitalised adults in England over the first seven months of the pandemic: An observational study using administrative data.

Authors:  William K Gray; Annakan V Navaratnam; Jamie Day; Julia Wendon; Tim W R Briggs
Journal:  Lancet Reg Health Eur       Date:  2021-04-30

4.  Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: A complex relationship.

Authors:  Cédric Dananché; Christelle Elias; Laetitia Hénaff; Sélilah Amour; Elisabetta Kuczewski; Marie-Paule Gustin; Vanessa Escuret; Mitra Saadatian-Elahi; Philippe Vanhems
Journal:  PLoS One       Date:  2022-01-07       Impact factor: 3.240

5.  Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study.

Authors:  Yin Mo; David W Eyre; Sheila F Lumley; Timothy M Walker; Robert H Shaw; Denise O'Donnell; Lisa Butcher; Katie Jeffery; Christl A Donnelly; Ben S Cooper
Journal:  PLoS Med       Date:  2021-10-12       Impact factor: 11.069

6.  Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.

Authors:  Jose María Álvaro Gracia; Carlos Sanchez-Piedra; Javier Manero; María Ester Ruiz-Lucea; Laura López-Vives; Cristina Bohorquez; Julia Martinez-Barrio; Gema Bonilla; Paloma Vela; María Jesús García-Villanueva; María Teresa Navío-Marco; Marina Pavía; María Galindo; Celia Erausquin; Miguel A Gonzalez-Gay; Inigo Rua-Figueroa; Jose M Pego-Reigosa; Isabel Castrejon; Jesús T Sanchez-Costa; Enrique González-Dávila; Federico Diaz-Gonzalez
Journal:  RMD Open       Date:  2021-12

7.  Comparative assessment of methods for short-term forecasts of COVID-19 hospital admissions in England at the local level.

Authors:  Sophie Meakin; Sam Abbott; Nikos Bosse; James Munday; Hugo Gruson; Joel Hellewell; Katherine Sherratt; Sebastian Funk
Journal:  medRxiv       Date:  2022-01-19

8.  The impact of remote home monitoring of people with COVID-19 using pulse oximetry: A national population and observational study.

Authors:  Chris Sherlaw-Johnson; Theo Georghiou; Steve Morris; Nadia E Crellin; Ian Litchfield; Efthalia Massou; Manbinder S Sidhu; Sonila M Tomini; Cecilia Vindrola-Padros; Holly Walton; Naomi J Fulop
Journal:  EClinicalMedicine       Date:  2022-03-01

9.  A risk scoring system to predict progression to severe pneumonia in patients with Covid-19.

Authors:  Ji Yeon Lee; Byung-Ho Nam; Mhinjine Kim; Jongmin Hwang; Jin Young Kim; Miri Hyun; Hyun Ah Kim; Chi-Heum Cho
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

10.  Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis.

Authors:  William Mude; Victor M Oguoma; Tafadzwa Nyanhanda; Lillian Mwanri; Carolyne Njue
Journal:  J Glob Health       Date:  2021-06-26       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.